68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617.

Lisa H de VriesLutske LodewijkArthur J A T BraatGerard C KrijgerGerlof D ValkMarnix G E H LamInne H M Borel RinkesMenno R VriensBart de Keizer

Published in: EJNMMI research (2020)

68Ga-PSMA PET/CT appears to have added value in patients with RAI-refractory DTC, as it is able to detect various types of lesions, some of which were not picked up by 18FDG PET/CT. Furthermore, 68Ga-PSMA PET/CT might be used to identify patients eligible for treatment with 177Lu-PSMA-617. One of the two patients who underwent 177Lu-PSMA-617 therapy showed a modest, temporary response. To draw conclusions about the effectiveness of this therapy, more research is needed.

Keyphrases

pet ct
end stage renal disease
positron emission tomography
chronic kidney disease
newly diagnosed
ejection fraction
prognostic factors
magnetic resonance imaging
computed tomography
squamous cell carcinoma
mesenchymal stem cells
magnetic resonance
bone marrow
young adults
combination therapy
patient reported